Diederik Stadig

Cross-border biotech deals between China and the United States are becoming more complex as the U.S. targets investment links, leading to potential slowdowns, according to analysts. Diederik Stadig of ING Research noted increased geopolitical scrutiny may result in fewer deals.

Cross-border biotech deals between China and the United States are becoming more complex due to increased U.S. efforts to restrict investment and technology transfers, with analysts predicting a modest slowdown. Geopolitical scrutiny is expected to lead to fewer deals, according to ING Research's Diederik Stadig.